PDHB drives the transcription of glycolysis-related genes and metabolic reprogramming by binding to the SLC2A1, GPI, and PKM2 promoters, thereby inducing sorafenib resistance in HCC (136). Here, SLC2A1 is linked to hepatocellular carcinoma.